ALK inhibitors (Positive control) and ABT199 (Proposed binding) in complex with the ALK active side. by Richard Junior Zapata Dongo (17912565)

Column charts of SI_8min and SI_10min in the therapy and control group at follow-up. by Felix L. Herr (21544362)

Subjects:

Representative CEUS images with BR55 of mice with a subcutaneous tumour allograft (arrows) under treatment. by Felix L. Herr (21544362)

Subjects:

Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

This is the data set that we used to reach the conclusions drawn in the manuscript with related metadata and methods. by Farayi Kaseke (19560197)

Subjects:

Data Sheet 1_Secretoneurin plasma levels are decreased after catheter ablation for atrial fibrillation—patients with AF produce lower SN levels than healthy individuals: the SAFE r... by Jiří Plášek (21805048)

“…</p>Conclusion<p>Plasma secretoneurin levels are decreased after catheter ablation for atrial fibrillation; patients with AF produce lower SN levels than healthy individuals. …”

Thermoneutrality decreased sepsis survival. by Goldia Chan (21453340)

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Decreased childhood asthma hospitalizations linked to hotter, drier climate with lower wind speed in drylands by Klézio Silva Monte (20579829)

Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side. by Hyung Suk Yang (20442438)

Subjects:

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects: